Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemiasRaphaël Itzykson, François Dreyfus, Odile Beyne‐Rauzy et al.|Leukemia|2011Cited by 464
TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs)Olivier Kosmider, Véronique Gelsi‐Boyer, Meyling Cheok et al.|Blood|2009Cited by 270
Oncogenic FLT3-ITD supports autophagy via ATF4 in acute myeloid leukemiaQuentin Heydt, Véronique Mansat‐De Mas|Oncogene|2017Cited by 113